#United States #New York #Securities Fraud #Pomerantz LLP #Journey Medical

Legal Concerns Surrounding Journey Medical Corporation

Investors are increasingly worried about the recent developments regarding Journey Medical Corporation (NASDAQ: DERM), prompting Pomerantz LLP to launch an investigation into potential claims of securities fraud. This investigation seeks to determine whether the company's executives have engaged in unlawful business practices that may have misled investors.

Financial Results and Analyst Questions

On March 25, 2026, Journey Medical released its financial results alongside a corporate update. The presentation drew considerable scrutiny, particularly when management highlighted discrepancies between prescription demand for their product, Emrosi, and the revenue they reported.

During this earnings call, executives explained that demand for Emrosi was indeed robust, fueled by reimbursement timing and co-pay assistance programs. However, they also candidly admitted that some prescriptions were not being reimbursed, impacting their co-pay assistance. This revelation raised eyebrows among analysts, especially as management asserted that the gross-to-net performance was still in alignment with expectations, creating a conflicting narrative about the company's actual financial health.

Reaction from Investors

The stock market reacted swiftly and negatively to these disclosures; on March 26, 2026, Journey's stock plummeted by $2.05 per share, accounting for a 30.01% decline and closing at $4.78. Such a dramatic fall indicates that investors may have lost confidence in the information released by the company.

Pomerantz LLP's Role

Pomerantz LLP, a renowned law firm with a rich history in corporate and securities class actions, is spearheading this investigation. Founded by Abraham L. Pomerantz, often referred to as the